Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,925 | -18,475 | -3,105 | -396 | -17,315 |
| Depreciation Amortization | 688 | 758 | 793 | 877 | 2,892 |
| Accounts receivable | N/A | N/A | 0 | 22 | -19 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 94 | 442 |
| Other Working Capital | 1,708 | 2,009 | 1,223 | 1,888 | 1,618 |
| Other Operating Activity | -9,199 | 15,029 | 103 | -3,227 | 9,841 |
| Operating Cash Flow | $122 | $-679 | $-987 | $-742 | $-2,541 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | N/A | -3 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $-3 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | -121 | 465 | 950 | 608 | 1,995 |
| Debt Repayment | N/A | N/A | N/A | N/A | -130 |
| Common Stock Issued | 11 | 142 | 126 | 100 | 168 |
| Other Financing Activity | -10 | -14 | -17 | 28 | 150 |
| Financing Cash Flow | $-120 | $593 | $1,059 | $736 | $2,183 |
| Beginning Cash Position | 0 | 86 | 13 | 19 | 379 |
| End Cash Position | 2 | 0 | 86 | 13 | 19 |
| Net Cash Flow | $2 | $-86 | $73 | $-6 | $-360 |
| Free Cash Flow | |||||
| Operating Cash Flow | 122 | -679 | -987 | -742 | -2,541 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -3 |
| Free Cash Flow | 122 | -679 | -987 | -742 | -2,544 |